IGF-1 lab reference ranges: what an optimal level looks like by age
A plain-English read on a routine lab number that quietly tracks your growth hormone story.
TL;DR
- IGF-1 is the most common lab marker for growth hormone activity because it is steadier in the blood than growth hormone itself.
- Reference ranges are age-banded and vary by laboratory. A normal number for a 30-year-old is different from a 60-year-old.
- A single out-of-range number is a starting point for a clinician conversation, not a diagnosis.
What it is
IGF-1 (in plain English: insulin-like growth factor 1, a circulating protein the liver makes in response to growth hormone) is the easier number to chase in a routine blood draw. Growth hormone itself is released in short pulses, mostly at night, and the level in your blood swings wildly from minute to minute. IGF-1, by contrast, is fairly steady through the day. Think of growth hormone as the spark and IGF-1 as the heat — the heat is what you can measure with a basic lab.
How it works
The hypothalamus signals the pituitary, the pituitary releases growth hormone, and growth hormone travels to the liver and tells it to make IGF-1 (Iranmanesh et al., J Clin Endocrinol Metab, 1991). IGF-1 then circulates and influences cell growth, repair, and metabolism in many tissues. Because growth hormone secretion declines by roughly 14 percent per decade of adult life, IGF-1 declines with it. Most clinical laboratories report IGF-1 against an age-banded reference range — sometimes shown by decade, sometimes by 5-year band.
Who asks about it
People come to this topic after a recent lab result lands in their inbox and they want to know whether the number is good. The honest answer is that the number alone tells you very little. Context — age, sex, time of draw, recent illness, body composition — all shape what is meaningful.
What the research says
A foundational 1991 study in the Journal of Clinical Endocrinology & Metabolism documented the age-related decline in growth hormone secretion that drives the parallel IGF-1 decline (Iranmanesh et al., 1991). A 2014 review in the same journal addressed the practical interpretation of IGF-1 in adults across age and clinical context (Yuen et al., J Clin Endocrinol Metab, 2014). The literature consistently emphasizes age-adjusted bands rather than a single universal target.
What to know before considering it
A single low or high IGF-1 result rarely diagnoses anything on its own. Repeat draws, additional labs, and clinical context are usually needed. Significantly low or high results in the absence of other findings still belong with a clinician — not a self-interpreted dashboard.
The Halftime POV
Numbers without context are noise. We use IGF-1 the way it was intended — as one signal in a panel, against an age-banded reference range, interpreted by someone trained to interpret it. That is the difference between a useful biomarker and a stressful one.
Related reading:
- IGF-1 lab test: what the number means
- Biomarkers commonly tracked during peptide protocols
- The baseline blood panel: what to test before any peptide protocol
FAQ
Q: What is IGF-1? A: IGF-1 is insulin-like growth factor 1, a circulating signal made primarily in the liver in response to growth hormone. It is the most common downstream marker used to estimate growth hormone activity, because IGF-1 is steadier in the blood than growth hormone itself.
Q: What is a normal IGF-1 level? A: Most laboratories report age-banded reference ranges. A common adult range falls roughly between 80 and 280 ng/mL, but the band that is normal for a 30-year-old is different from a 60-year-old. Always compare against your lab’s age-specific range.
Q: What does a low or high IGF-1 mean? A: A low IGF-1 may reflect age-related growth hormone decline, malnutrition, liver disease, or pituitary issues. A high IGF-1 can occur with rare pituitary tumors. A single number out of range is a starting point for a conversation with a clinician, not a diagnosis.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
